US 12,263,199 B2
Use of Sida rhombifolia
Eun Ju Jeong, Jinju-si (KR); Sangho Choi, Daejeon (KR); Randall Garcia Viquez, Santo Domingo (CR); Silvia Soto Montero, Santo Domingo (CR); Soo-Yong Kim, Daejeon (KR); Dong-Keun Yi, Daejeon (KR); and Nelson Zamora Villalobos, Santo Domingo (CR)
Assigned to INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY, Jinju-Si (KR); and KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, Daejeon (KR)
Appl. No. 17/423,078
Filed by INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY, Jinju-Si (KR); and KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, Daejeon (KR)
PCT Filed Jan. 15, 2020, PCT No. PCT/KR2020/000751
§ 371(c)(1), (2) Date Jul. 14, 2021,
PCT Pub. No. WO2020/149645, PCT Pub. Date Jul. 23, 2020.
Claims priority of application No. 10-2019-0005875 (KR), filed on Jan. 16, 2019; and application No. 10-2020-0004754 (KR), filed on Jan. 14, 2020.
Prior Publication US 2022/0080010 A1, Mar. 17, 2022
Int. Cl. A61K 36/185 (2006.01); A23L 33/105 (2016.01); A61P 13/08 (2006.01)
CPC A61K 36/185 (2013.01) [A23L 33/105 (2016.08); A61P 13/08 (2018.01)] 4 Claims
 
1. A method of treating, ameliorating, or inhibiting benign prostatic hyperplasia, the method comprising administering an effective amount of Sida rhombifolia to a subject in need thereof, wherein the Sida rhombifolia is prepared as a solvent extract and the treating, the ameliorating, or the inhibiting is achieved by at least one effect selected from inhibition of 5-alpha reductase activity, inhibition of 5-alpha reductase expression, and inhibition of dihydrotestosterone production.